SecBot SecBot
DEFM14A ·Filed Nov 13, 2026

LFCR

LIFECORE BIOMEDICAL, INC. \DE\
NEUTRAL
Impact 6/10
Horizonweeks Processed3d 9h ago SEC0001140361-26-043742
Notable filing: DEFM14A
Actionable Insight • Neutral

The merger is fully financed with no financing condition, HSR clearance obtained, and ~27.4% of votes already committed. The key remaining condition is stockholder approval at the December 23 special meeting. Monitor for any stockholder litigation or appraisal demands that could delay closing, but the deal appears on track to close by end of Q4 2026.

DirectionNeutral
Confidencehigh
Horizonweeks
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical is being acquired by affiliates of Webster Equity Partners for $6.28 per share in cash plus one contingent value right (CVR) per share. The deal values the company at approximately $238 million in equity consideration (based on 37.9M common shares outstanding). The board unanimously recommends approval, and holders of ~27.4% of voting power have already agreed to vote in favor. The special meeting is scheduled for December 23, 2026.

Key Financial Metrics

Deal Value
$238.0M
Deal Type
merger

Key Facts

  • Merger consideration: $6.28 per share in cash plus one CVR per share
  • Series A Preferred Stock holders receive Conversion Amount ($1,000/share + $18.125 accrued dividends as of Sept 27, 2026) plus CVRs
  • Total funds needed at closing: approximately $550 million, funded by $400M equity commitment and $150M debt commitment ($115M term loans + $30M revolver + $35M Alcon term loan)
  • HSR waiting period terminated early on November 4, 2026
  • Voting and support agreements cover ~27.37% of combined voting power (Wynnefield and Legion stockholders)
  • Company termination fee: $9,957,716 ($7,468,287 during go-shop period); Reverse termination fee: $16,181,288
  • Board and Transaction Committee unanimously recommend FOR the merger
  • Craig-Hallum delivered fairness opinion that the common stock merger consideration is fair from a financial point of view
  • Appraisal rights available under Delaware law for dissenting stockholders
  • Go-shop period ended October 28, 2026 with no acquisition proposal received

Financial Impact

Total equity consideration approximately $238M based on 37.9M common shares at $6.28/share, plus CVRs with milestone payments; total deal financing ~$550M

share priceequity valuedilution

Risk Factors

  • Failure to obtain stockholder approval (majority of combined voting power required)
  • Stockholder appraisal demands could create uncertainty or delay
  • CVR payments are contingent on future milestones and may be zero
  • Alcon is both a major customer and a lender in the debt financing, creating potential conflicts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001140361-26-043742
Document: ny20082863x2_defm14a.htm0001140361-26-043742

Track record

20 reports on LFCR

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Viewing Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026